
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy/Economic_IndiaTimes
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
In the intricate realm of biotech, Eyestem Research stands at the forefront, navigating a challenging path towards regulatory approval. The recently submitted Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) marks a pivotal moment for Eyestem’s therapy, Eyecyte-RPE. This groundbreaking treatment aims to address medium- and late-stage geographic atrophy, secondary to dry AMD, providing hope for patients.
Global Regulatory Landscape: A Balancing Act
Jogin Desai, CEO of Eyestem Research, sheds light on the complex dance with global regulatory agencies. Harmonization efforts are underway, with common technical documents acting as beacons across India, Australia, and Singapore. Desai emphasizes the importance of understanding each country’s unique regulatory nuances, be it India’s stringent input controls or Australia’s reliance on output controls.
The Rigorous Path to Clinical Stage: From Idea to Approval
Desai unravels the intricate lifecycle of a biotech company, detailing the rigorous journey from ideation to clinical-stage readiness. Animal trials, proof of concept, efficacy studies, and toxicity assessments constitute the arduous path. IND approval signifies a company’s maturity, signaling to investors and paving the way for impactful biotech solutions.
As Eyestem aims for IND approval, its CEO envisions a future where the company addresses not only dry AMD but also Parkinson’s and retinitis pigmentosa. With a commitment to affordability, Eyestem strives to revolutionize the cost paradigm in cell and gene therapies, offering a beacon of hope for patients globally.
In collaboration with renowned institutions like AIIMS in Delhi and LV Prasad Eye Institute, Eyestem Research propels regenerative therapies forward, setting new standards in ophthalmology. Beyond its immediate impact, this partnership hints at the transformative role Eyestem may play in the evolution of personalized and regenerative medicine.
Latest Posts
- US believes Iran hasn’t decided to build a nuclear weapon
October 11, 2024 | Breaking News, United States of America, World - Realme Narzo Phones Confirmed to Launch in India Soon via Amazon
December 6, 2025 | Breaking News, Tech - Nothing Phone 3a Lite Goes on Sale in India: See Price, Offers, Availability
December 6, 2025 | Tech - NVIDIA Needed Just $2200 to Make Investors Millionaires
December 6, 2025 | Business, World - Entertainment Shake-Up: Netflix Nears $83 Billion Acquisition of Warner Bros. Discovery
December 5, 2025 | Breaking News, Tech - Bilateral Trade Between India and Russia to Reach $100 Billion, Putin Says
December 5, 2025 | Breaking News, World - Putin Ordered 2018 Novichok Poisoning Of Ex-Russian Spy: UK Inquiry
December 5, 2025 | Breaking News, World - MoneyHero and Coinbase Jointly Publish Pulse of Crypto — Singapore 2025 Survey Report
November 20, 2025 | Breaking News, World - Kwikset Honored in SecurityInfoWatch.com Readers’ Choice Awards
November 18, 2025 | World - RapidAI Earns FDA Clearance for Rapid Aortic, Bringing AI-Driven Aortic Measurements and Surveillance to Care Teams
November 18, 2025 | AI & ML, Breaking News, World - Valeura Implements New Share Buyback Programme
November 18, 2025 | Breaking News, Business
